Get to know our clinical trials

Phase 1b dose-escalation clinical trial of OMTX705, an antibody-drug conjugate directed against fibroblast activation protein in combination with gemcitabine/nab-paclitaxel and tislelizumab

Imagen del Dr. Mariano Ponz -Sarvisé, especialista en Oncología Médica de la Clínica Universidad de Navarra. El Dr. Ponz-Sarvisé se dedica preferencialmente a los tumores de páncreas y vías biliares.
Dr. Mariano Ponz-Sarvisé Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Liver and Pancreatic Cancer Area
Status
In recruitment
headquarters
Pamplona
Early phase

Technical Summary

  • PHASE 1B DOSE-ESCALATION CLINICAL TRIAL OF OMTX705, AN ANTIBODY-DRUG CONJUGATE DIRECTED AGAINST FIBROBLAST ACTIVATION PROTEIN (FAP), IN COMBINATION WITH GEMCITABINE/NAB-PACLITAXEL AND TISLELIZUMAB, IN PATIENTS WITH ADVANCED-STAGE OR METASTATIC PANCREATIC ADENOCARCINOMA.
  • Code EudraCT: 2025-521872-69
  • Protocol number: OMTX705-006
  • Promoter: Oncomatryx Biopharm S.L.
  • Molecule/Drug: OMTX705

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION